LDS/Medical Tests/WRAP53 Gene Mutation Analysis

WRAP53 Gene Mutation Analysis

The WRAP53 (WD40-encoding RNA antisense to p53) gene is located in the short (p) arm of chromosome 17 at position 13.1. WRAP53 gene encodes an important component of the telomerase complex required for telomere synthesis. The WRAP53 mRNA also functions as p53 antisense transcript and is involved in p53 tumor suppressor regulation. Mutations in WRAP53 is associated with an autosomal recessive form of dyskeratosis congenita.

Dyskeratosis congenita is a telomere biology disorder characterized by a classic triad of dysplastic nails, lacy reticular pigmentation of the upper chest and neck and oral leukoplakia. DC may be inherited as an autosomal dominant disorder caused by mutations in ACD, CTC1, DKC1, NHP2, PARN, RTEL1, TERC, TERT, TINF2 and NOP10; or as an autosomal recessive disorder due to mutations in ACD, CTC1, NHP2, NOP10, PARN, RTEL1, STN1, TERT, or WRAP53; or rarely as an X-linked recessive disorder due to mutations in DKC1 (Hoyeraal Hreidarsson syndrome). In addition to the clinical features listed above, individuals with dyskeratosis congenita have an increased risk of developing pulmonary fibrosis, bone marrow failure, myelodysplasia, acute myelogenous leukemia, and solid tumors (typically squamous carcinoma of the head/neck and anogenital carcinoma). Despite the mode of inheritance all forms of DC result in an inability of cells to maintain telomere length during cell division resulting in premature cell dysfunction and death.

  • Diagnostic confirmation of dyskeratosis congenita
  • Carrier screening in family members of the affected patient
  • For prenatal diagnosis in at-risk pregnancies

Positive: Mutation or pathogenic variant in WRAP53 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative: No mutation or pathogenic variant in WRAP53 gene.

Negative for mutation or pathogenic variant in WRAP53 gene

Sequence analysis of the entire coding region by bi-directional Sanger sequence analysis Targeted variant analysis by bi-directional Sanger sequence analysis, Next generation sequencing.

Whole blood (EDTA), Cultured fibroblasts, Skin biopsy.

Stability (whole blood)

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unacceptable
Telomer gene mutation panel by NGS. Bone marrow biopsy, Hereditary Cancer Panel, Comprehensive Epilepsy Panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login